Investor Relations

Webcast ImageWebcast
Navidea Biopharmaceuticals Inc Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers  (Replay)
07/08/14 at 8:00 a.m. ET
Navidea Biopharmaceuticals Inc Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers
Tuesday, July 8, 2014 8:00 a.m. ET  through Tuesday, July 8, 2014 
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Q3 2014 Navidea Biopharmaceuticals Inc Earnings Conference Call (Replay)
11/06/14 at 8:30 a.m. ET
Q3 2014 Navidea Biopharmaceuticals Inc Earnings Conference Call
Thursday, November 6, 2014 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Navidea Biopharmaceuticals, a leader in precision diagnostics, is a biopharmaceutical company developing novel radiopharmaceutical imaging agents to help identify the presence and status of disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea Biopharmaceuticals’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. The company, founded in 1983, maintains headquarters in Dublin, Ohio and recently changed its name from Neoprobe following the sale of its medical device business.

Today's Quote

NAVB (Common Stock)
ExchangeNYSE Amex (US Dollar)
Price$1.79
Change (%) Stock is Up 0.05 (2.87%)
Volume2,449,006
Data as of 12/19/14 4:10 p.m. ET
Minimum 20 minute delay
Refresh quote

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.